Materias dentro de su búsqueda.
Mostrando 1,681 - 1,700 Resultados de 1,900 Para Buscar '"AstraZeneca"', tiempo de consulta: 0.17s Limitar resultados
  1. 1681
    “…The National Institute for Health and Care Excellence (NICE) invited AstraZeneca, the manufacturer of ticagrelor (Brilique(®)), to submit evidence on the clinical and cost effectiveness of ticagrelor 60 mg twice daily (BID) in combination with low-dose aspirin [acetylsalicylic acid (ASA)] compared with ASA only for secondary prevention of atherothrombotic events in patients with a history of myocardial infarction (MI) and who are at increased risk of atherothrombotic events. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Ticagrelor for Secondary Prevention of Atherothrombotic Events After Myocardial Infarction: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
  2. 1682
    por Jankowski, Janusz A Z, de Caestecker, John, Love, Sharon B, Reilly, Gavin, Watson, Peter, Sanders, Scott, Ang, Yeng, Morris, Danielle, Bhandari, Pradeep, Attwood, Stephen, Ragunath, Krish, Rameh, Bashir, Fullarton, Grant, Tucker, Art, Penman, Ian, Rodgers, Colin, Neale, James, Brooks, Claire, Wise, Adelyn, Jones, Stephen, Church, Nicholas, Gibbons, Michael, Johnston, David, Vaidya, Kishor, Anderson, Mark, Balata, Sherzad, Davies, Gareth, Dickey, William, Goddard, Andrew, Edwards, Cathryn, Gore, Stephen, Haigh, Chris, Harding, Timothy, Isaacs, Peter, Jackson, Lucina, Lee, Thomas, Lim, Peik Loon, Macdonald, Christopher, Mairs, Philip, McLoughlin, James, Monk, David, Murdock, Andrew, Murray, Iain, Preston, Sean, Pugh, Stirling, Smart, Howard, Soliman, Ashraf, Todd, John, Turner, Graham, Worthingon, Joy, Harrison, Rebecca, Barr, Hugh, Moayyedi, Paul
    Publicado 2018
    “…FUNDING: Cancer Research UK, AstraZeneca, Wellcome Trust, and Health Technology Assessment.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial
  3. 1683
    “…FUNDING: Medical Research Council (MRC) and National Institute for Health Research (NIHR) Efficacy and Mechanism Evaluation programme, Cancer Research UK, NIHR Clinical Trials Research Network, Health and Care Research Wales, and AstraZeneca.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial
  4. 1684
    “…Red Hill: Consultant, Consulting fee. AstraZeneca: CME, Speaker honorarium. Q. Zhang, Insmed Incorporated: Employee, Salary. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    122. All-Cause Mortality Increased With Nontuberculous Mycobacterial Lung Disease in US Medicare
  5. 1685
    “…Marras, Insmed Incorporated: Investigator, Consulting fee and Research grant, Horizon Pharmaceuticals: Consultant, Consulting fee, Red Hill: Consultant, Consulting fee, AstraZeneca: CME, Speaker honorarium. G. Eagle, Insmed Incorporated: Employee, Salary. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    780. Incidence and Prevalence of Nontuberculous Mycobacterial Lung Disease in US Medicare, 2008–2015
  6. 1686
    “…FUNDING: Cancer Research UK and AstraZeneca.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial
  7. 1687
    “…The combination of capivasertib and fulvestrant warrants further investigation in phase 3 trials. FUNDING: AstraZeneca and Cancer Research UK.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial
  8. 1688
    “…Cedars—no conflicts; Dr Richard Legro—consultant for Ogeda, Millendo, Kindex and Bayer; Ferring and Astra Zeneca funding; Dr Stephen A. Krawetz—no conflicts; Dr Christos Coutifaris—NIH Funding; Dr Hao Huang—no conflicts; Dr Nanette Santoro—no conflicts; Dr Heping Zhang—NIH Funding. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Families with children resulting from ART: psychosocial and financial implications
  9. 1689
    “…J.B. reports grants from Amgen, AstraZeneca, Pfizer, Roche, Sanofi-Aventis and Merck, outside the submitted work, and payment from UpToDate to Asklepios Medicine HB for a chapter on BC prediction and prognostication. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Efficacy and safety of controlled ovarian stimulation using GnRH antagonist protocols for emergency fertility preservation in young women with breast cancer—a prospective nationwide Swedish multicenter study
  10. 1690
    “…J.T.G. has undertaken consultancy work for AstraZeneca and Takeda Pharmaceuticals and is an employee of Boehringer Ingelheim. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Kisspeptin and neurokinin B interactions in modulating gonadotropin secretion in women with polycystic ovary syndrome
  11. 1691
    “…(Consultant, Advisor or Review Panel member, Research Grant or Support) Bart Jan Kullberg, MD, FRCP, FIDSA, Amplyx (Advisor or Review Panel member) Galia Rahav, MD, AstraZeneca (Scientific Research Study Investigator) Mickaël Aoun, MD, Amplyx Pharmaceuticals (Scientific Research Study Investigator) Pierre Bulpa, MD, Amplyx Pharmaceuticals (Scientific Research Study Investigator) Ricard Ferrer, MD, PhD, Shionogi B.V. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    147. Clinical Safety and Efficacy of Novel Antifungal, Fosmanogepix, in the Treatment of Candidemia: Results from a Phase 2 Proof of Concept Trial
  12. 1692
    “…METHODS: In a multicenter observational pilot study, 2 weeks after a first vaccination (BNT162b2/Pfizer-BioNTech [Comirnaty] or ChAdOx1 nCoV-19/Oxford-Astra-Zeneca [Vaxzevria]), hemodialysis patients (N = 23), peritoneal dialysis patients (N = 4) and healthy staff (N = 14) were tested for SARS-CoV-2-spike IgG/IgM, Nucleocapsid-protein-IgG-antibodies and plasma ACE2-receptor-binding-inhibition capacity. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Immunogenicity of a first dose of mRNA- or vector-based SARS-CoV-2 vaccination in dialysis patients: a multicenter prospective observational pilot study
  13. 1693
    “…Martins da Silva reports grants from AstraZeneca, during the conduct of the study; and is Associate editor of Human Reproduction and Editorial Board member of Reproduction and Fertility. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A randomised controlled trial to assess the clinical effectiveness and safety of the endometrial scratch procedure prior to first-time IVF, with or without ICSI
  14. 1694
    “…INTERPRETATION: In patients with cardiometabolic risk factors who were hospitalised with COVID-19, treatment with dapagliflozin did not result in a statistically significant risk reduction in organ dysfunction or death, or improvement in clinical recovery, but was well tolerated. FUNDING: AstraZeneca.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial
  15. 1695
    “…In this study we aimed to assess the antibody and cellular responses of older people after a single dose of either the BNT162b2 vaccine (tozinameran; Pfizer–BioNTech) or ChAdOx1 nCoV-19 vaccine (Oxford University–AstraZeneca). METHODS: Participants aged 80 years or older, who did not live in a residential or care home or require assisted living, and had received a single dose of either the BNT162b2 vaccine or ChAdOx1 nCoV-19 vaccine were eligible to participate. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Immunogenicity of single vaccination with BNT162b2 or ChAdOx1 nCoV-19 at 5–6 weeks post vaccine in participants aged 80 years or older: an exploratory analysis
  16. 1696
    “…CASE SUMMARY: Herein, we present two cutaneous T-cell lymphoma (CTCL) cases which were in long-term remission and experienced a flare after immunization with a viral vector COVID-19 vaccine (Vaxzevria, Oxford/AstraZeneca). The first case was a 60-year-old male with early-stage (T1a) folliculotropic mycosis fungoides (MF) clinically presented as alopecia areata-like lesions. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Cutaneous T-cell lymphoma (CTCL) exacerbation after viral vector COVID-19 vaccination
  17. 1697
    “…A.W.H. reports grant funding from the MRC, NIHR, CSO, Wellbeing of Women, Roche Diagnostics, Astra Zeneca, Ferring, Charles Wolfson Charitable Trust, Standard Life, Consultancy fees from Roche Diagnostics, AbbVie, Nordic Pharma and Ferring, outside the submitted work. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    An international terminology for endometriosis, 2021(,)
  18. 1698
    “…A.W.H. reports grant funding from the MRC, NIHR, CSO, Wellbeing of Women, Roche Diagnostics, Astra Zeneca, Ferring, Charles Wolfson Charitable Trust, Standard Life, Consultancy fees from Roche Diagnostics, AbbVie, Nordic Pharma and Ferring, outside the submitted work. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Endometriosis classification, staging and reporting systems: a review on the road to a universally accepted endometriosis classification(,)
  19. 1699
    “…After second vaccination there was no difference in the percentage of patients with a positive result between those who received the Pfizer (30/35, 85.7%) and AstraZeneca (28/34, 82.4%) vaccine, nor was there a difference with sex or age. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    P-144: Response to SARS-CoV-2 vaccination in patients with Multiple Myeloma using a 12-week spaced dosing strategy
  20. 1700
    “…La survenue de l’EN a eu lieu respectivement 2, 4 et 3 jours après la deuxième injection du vaccin AstraZeneca. Aucune patiente ne rapportait d’épisode infectieux précessif. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Érythème noueux post-vaccin anti-COVID-19 : 3 cas
Herramientas de búsqueda: RSS